Olmesartan/Amlodipin/Hydrochlorothiazid Glenmark (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartan/Amlodipin/Hydrochlorothiazid Glenmark, is a angiotensin II receptor blocker presented as a combination tablet for oral use. It treats hypertension in adults, often in combination with other antihypertensive agents. GNH USA supplies Olmesartan/Amlodipin/Hydrochlorothiazid Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan/Amlodipin/Hydrochlorothiazid Glenmark is a fixed‑dose combination that brings together three antihypertensive agents to provide complementary blood‑pressure‑lowering effects in a single tablet.

Olmesartan/Amlodipin/Hydrochlorothiazid Glenmark is used for managing high blood pressure through several complementary mechanisms. - Hypertension: lowers systolic and diastolic blood pressure when monotherapy is insufficient. - Hypertension with fluid retention: adds diuretic effect to improve control. - Hypertension in patients requiring calcium‑channel blockade: provides vasodilation alongside renin‑angiotensin inhibition. - Hypertension resistant to single‑agent therapy: offers triple‑component synergy for better target achievement. - Hypertension in elderly patients: simplifies regimen with once‑daily dosing. - Hypertension with metabolic considerations: allows dose titration of each component as needed.

Common Side Effects: - Headache: mild to moderate headache may occur. - Peripheral edema: swelling of ankles or feet is frequently reported. - Dizziness: especially after the first doses or rapid posture changes. - Fatigue: a general feeling of tiredness can be experienced. - Flushing: transient warmth or redness of the skin. - Cough: occasional dry cough, more typical of angiotensin‑blocking agents.

Serious or Rare Side Effects: - Hyperkalemia: elevated potassium levels requiring monitoring. - Acute kidney injury: sudden decline in renal function. - Severe hypotension: marked drop in blood pressure leading to fainting. - Hepatic dysfunction: abnormal liver enzymes or hepatitis. - Angio‑edema: swelling of face, lips, tongue or airway. - Blood dyscrasias: rare blood‑cell abnormalities such as agranulocytosis.

Olmesartan/Amlodipin/Hydrochlorothiazid Glenmark should be used with caution in specific clinical situations. - Renal impairment: monitor kidney function and electrolytes regularly. - Hepatic disease: dose adjustment may be required; watch for liver enzyme changes. - Electrolyte imbalance: especially potassium and sodium levels need periodic checks. - Pregnancy: avoid use; drug is contraindicated in the first trimester and beyond. - Elderly patients: start at lower dose and assess tolerance. - Drug‑induced photosensitivity: advise patients to use sun protection. - Store at ambient temperature: keep below 25°C, protect from moisture and light.

Olmesartan/Amlodipin/Hydrochlorothiazid Glenmark may interact with several medicines. Major Interactions (Avoid): - Potassium‑rich supplements or salts: risk of hyper‑kalemia. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase amlodipine levels. - NSAIDs (high dose): may blunt antihypertensive effect and affect renal function. Moderate Interactions (Monitor Closely): - Lithium: may increase lithium concentrations. - Diuretics other than hydrochlorothiazide: additive electrolyte disturbances. - ACE inhibitors or ARBs: risk of excessive potassium loss and renal impairment.